ES8607397A1 - Metodo para la preparacion del factor viii humano funcional - Google Patents
Metodo para la preparacion del factor viii humano funcionalInfo
- Publication number
- ES8607397A1 ES8607397A1 ES542296A ES542296A ES8607397A1 ES 8607397 A1 ES8607397 A1 ES 8607397A1 ES 542296 A ES542296 A ES 542296A ES 542296 A ES542296 A ES 542296A ES 8607397 A1 ES8607397 A1 ES 8607397A1
- Authority
- ES
- Spain
- Prior art keywords
- factor viii
- human factor
- materials
- production
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60231284A | 1984-04-20 | 1984-04-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES8607397A1 true ES8607397A1 (es) | 1986-06-01 |
| ES542296A0 ES542296A0 (es) | 1986-06-01 |
Family
ID=24410850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES542296A Expired ES8607397A1 (es) | 1984-04-20 | 1985-04-16 | Metodo para la preparacion del factor viii humano funcional |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP0160457B1 (enExample) |
| JP (2) | JP2799338B2 (enExample) |
| KR (1) | KR850007275A (enExample) |
| AR (1) | AR241314A1 (enExample) |
| AT (1) | ATE60087T1 (enExample) |
| AU (2) | AU601358B2 (enExample) |
| CA (2) | CA1341395C (enExample) |
| DE (1) | DE3581312D1 (enExample) |
| DK (1) | DK164876C (enExample) |
| ES (1) | ES8607397A1 (enExample) |
| FI (1) | FI86885C (enExample) |
| GR (1) | GR850947B (enExample) |
| HK (1) | HK8395A (enExample) |
| HU (1) | HU202275B (enExample) |
| IE (1) | IE57677B1 (enExample) |
| IL (1) | IL74909A (enExample) |
| LU (1) | LU88546I2 (enExample) |
| MY (1) | MY102029A (enExample) |
| NL (1) | NL940016I2 (enExample) |
| NO (1) | NO174934C (enExample) |
| NZ (1) | NZ211824A (enExample) |
| PT (1) | PT80292B (enExample) |
| ZA (1) | ZA852864B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657894A (en) * | 1983-03-31 | 1987-04-14 | Scripps Clinic & Research Foundation | New factor VIII coagulant polypeptides |
| JPH07106156B2 (ja) * | 1983-10-28 | 1995-11-15 | ジェネティックス、インスティチュ−ト | ファクタ−▲viii▼および関連生産物の製造 |
| US5004804A (en) * | 1984-01-12 | 1991-04-02 | Nordisk Gentofte | Method and composition for preparation of factor VIIIC |
| US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
| US4716117A (en) * | 1984-10-26 | 1987-12-29 | Chiron Corporation | Monoclonal antibodies to factor VIIIC |
| DE10399009I1 (de) * | 1984-01-12 | 2003-10-23 | Chiron Corp | F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen |
| US5045455A (en) * | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
| ZA852099B (en) * | 1984-03-26 | 1985-12-24 | Meloy Lab | Recombinant factor viii-c. |
| FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| EP0182448A3 (en) * | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
| ES8801674A1 (es) * | 1985-04-12 | 1988-02-16 | Genetics Inst | Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante. |
| US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| EP0251843A1 (fr) * | 1986-06-06 | 1988-01-07 | Transgene S.A. | Procédé de préparation de facteur VIII à partir de cellules de mammifères |
| FR2599754B1 (fr) * | 1986-06-06 | 1989-12-29 | Transgene Sa | Procede de preparation de facteur viii a partir de cellules de mammiferes |
| EP0254076B1 (en) | 1986-07-11 | 1991-05-08 | Miles Inc. | Improved recombinant protein production |
| NO872932L (no) * | 1986-07-18 | 1988-01-19 | Gist Brocades Nv | Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika. |
| AU613316B2 (en) * | 1986-09-12 | 1991-08-01 | Genentech Inc. | Improved recombinant expression |
| JP2872255B2 (ja) * | 1987-01-30 | 1999-03-17 | バイオジエン,インコーポレイティド | ファクター▲viii▼の高収量生産法 |
| US6060447A (en) * | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| IL86693A (en) * | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| EP0294910B1 (en) * | 1987-06-12 | 1996-09-11 | Immuno Ag | Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| JPH0387173A (ja) * | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体 |
| JP2791418B2 (ja) | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | 異種蛋白質の製造方法、組換えdna、形質転換体 |
| FR2642767B1 (fr) * | 1989-01-19 | 1993-10-01 | Transgene Sa | Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation |
| NZ237244A (en) * | 1990-03-02 | 1992-10-28 | Bio Technology General Corp | Cloning and production of human von willebrand factor analogues and compositions thereof |
| US5849536A (en) * | 1990-03-02 | 1998-12-15 | Bio-Technology General Corp. | Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same |
| US6008193A (en) * | 1990-03-02 | 1999-12-28 | Bio-Technology General Corp. | Methods of using human von Willebrand factor GPIb binding domain polypeptides |
| US5279956A (en) * | 1991-06-24 | 1994-01-18 | The Scripps Research Institute | Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C |
| DK53792D0 (da) * | 1992-04-24 | 1992-04-24 | Novo Nordisk As | Fremgangsmaade til fremstilling af proteiner |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| SE9303601D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Improved cell cultivation method and medium |
| US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
| IL113010A (en) * | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| US5561053A (en) * | 1994-08-05 | 1996-10-01 | Genentech, Inc. | Method for selecting high-expressing host cells |
| SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
| SE503424C2 (sv) * | 1994-11-14 | 1996-06-10 | Pharmacia Ab | Process för rening av rekombinant koagulationsfaktor VIII |
| GB9501040D0 (en) | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| US7005505B1 (en) | 1995-08-25 | 2006-02-28 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
| US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| US5910481A (en) * | 1995-11-13 | 1999-06-08 | Immuno Ag | Hybrid proteins with modified activity |
| AT405740B (de) * | 1996-12-13 | 1999-11-25 | Immuno Ag | Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| JP4663837B2 (ja) * | 1999-12-24 | 2011-04-06 | 一般財団法人化学及血清療法研究所 | 第▲viii▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物 |
| EE200200538A (et) * | 2000-03-22 | 2004-04-15 | Octagene Gmbh | Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides |
| US7220718B2 (en) | 2001-08-03 | 2007-05-22 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oral treatment of hemophilia |
| CN1596310A (zh) * | 2001-11-28 | 2005-03-16 | 桑多斯有限公司 | 产生重组多肽的方法 |
| EP2287288B1 (en) | 2002-07-09 | 2012-11-07 | Baxter International Inc. | Animal protein free media for cultivation of cells |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| EP1707634A1 (en) | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| WO2011095604A1 (en) | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| TR201908020T4 (tr) | 2011-02-17 | 2019-06-21 | Univ Pennsylvania | Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler. |
| WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
| EP3283126B1 (en) | 2015-04-16 | 2019-11-06 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
| CN111504887B (zh) * | 2020-05-09 | 2023-05-09 | 苏州四正柏生物科技有限公司 | 一种溶血素及其制备方法 |
| WO2022032140A2 (en) | 2020-08-07 | 2022-02-10 | Amicus Therapeutics, Inc. | Vesicle targeting proteins and uses of same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361509A (en) * | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| EP0107278B1 (en) * | 1982-08-04 | 1989-11-15 | National Research Development Corporation | Molecular cloning of the gene for human anti-haemophilic factor ix |
| IE80638B1 (en) * | 1983-03-31 | 1998-10-21 | Scripps Research Inst | Monoclonal antibodies to new factor VIII coagulant polypeptides |
| JPH07106156B2 (ja) * | 1983-10-28 | 1995-11-15 | ジェネティックス、インスティチュ−ト | ファクタ−▲viii▼および関連生産物の製造 |
| DE10399009I1 (de) * | 1984-01-12 | 2003-10-23 | Chiron Corp | F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen |
| ZA852099B (en) * | 1984-03-26 | 1985-12-24 | Meloy Lab | Recombinant factor viii-c. |
| FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| JPS60224492A (ja) * | 1984-04-24 | 1985-11-08 | Yuu Honshiyo | 異種遺伝子の結合法 |
-
1985
- 1985-04-15 FI FI851497A patent/FI86885C/fi not_active IP Right Cessation
- 1985-04-15 IL IL74909A patent/IL74909A/xx not_active IP Right Cessation
- 1985-04-16 ES ES542296A patent/ES8607397A1/es not_active Expired
- 1985-04-16 AR AR85300095A patent/AR241314A1/es active
- 1985-04-16 PT PT80292A patent/PT80292B/pt unknown
- 1985-04-17 HU HU851428A patent/HU202275B/hu unknown
- 1985-04-17 ZA ZA852864A patent/ZA852864B/xx unknown
- 1985-04-17 CA CA000617007A patent/CA1341395C/en not_active Expired - Fee Related
- 1985-04-17 AU AU41345/85A patent/AU601358B2/en not_active Expired
- 1985-04-17 NZ NZ211824A patent/NZ211824A/en unknown
- 1985-04-17 CA CA000479409A patent/CA1341468C/en not_active Expired - Fee Related
- 1985-04-18 NO NO851563A patent/NO174934C/no not_active IP Right Cessation
- 1985-04-18 EP EP85302734A patent/EP0160457B1/en not_active Expired - Lifetime
- 1985-04-18 AT AT85302734T patent/ATE60087T1/de active
- 1985-04-18 GR GR850947A patent/GR850947B/el not_active IP Right Cessation
- 1985-04-18 DE DE8585302734T patent/DE3581312D1/de not_active Expired - Lifetime
- 1985-04-18 IE IE998/85A patent/IE57677B1/en not_active IP Right Cessation
- 1985-04-18 LU LU88546C patent/LU88546I2/fr unknown
- 1985-04-18 EP EP19900200797 patent/EP0385558A3/en not_active Withdrawn
- 1985-04-19 DK DK176885A patent/DK164876C/da not_active IP Right Cessation
- 1985-04-19 JP JP60085295A patent/JP2799338B2/ja not_active Expired - Lifetime
- 1985-04-19 KR KR1019850002651A patent/KR850007275A/ko not_active Ceased
-
1987
- 1987-09-24 MY MYPI87001923A patent/MY102029A/en unknown
-
1990
- 1990-04-05 AU AU52958/90A patent/AU5295890A/en not_active Abandoned
-
1993
- 1993-04-20 JP JP5093222A patent/JP2777043B2/ja not_active Expired - Lifetime
-
1994
- 1994-08-24 NL NL940016C patent/NL940016I2/nl unknown
-
1995
- 1995-01-19 HK HK8395A patent/HK8395A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES8607397A1 (es) | Metodo para la preparacion del factor viii humano funcional | |
| FI883082A0 (fi) | Konstruering av syntetisk dna och dess anvaendning i syntes av stora polypeptider. | |
| FI852547L (fi) | Framstaellning av faktor viii och daertill hoerande produkter. | |
| ES2056817T3 (es) | Transformacion de trichoderma. | |
| ATE87317T1 (de) | Fsh. | |
| ES2146572T3 (es) | Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano. | |
| ATE198754T1 (de) | Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung | |
| ES2147553T3 (es) | Vectores virales recombinantes para la expresion en unas celulas musculares. | |
| ES2151463T1 (es) | Constructos de adn para la modificacion de la activacion y expresion de genes endogenos. | |
| ES2060594T3 (es) | Proceso para purificar proteinas recombinantes y uso de productos de las mismas. | |
| DE10075011I2 (de) | Rezeptoren für Tumornekrosisfaktor-alpha und-beta. | |
| ES2137931T3 (es) | Proteinas gdf-1 y uog-1. | |
| MX9302917A (es) | Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene. | |
| ES2142801T3 (es) | Clonacion y expresion de luciferasa de renilla. | |
| ES2091916T3 (es) | Metodo para suministrar moleculas en el interior de celulas eucarioticas. | |
| PT892849E (pt) | Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico | |
| ATE323770T1 (de) | Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren | |
| DK388789D0 (da) | Hybridderivat af humant protein d, dets fremstilling og anvendelse samt dna, som koder derfor, og genstruktur og vaertscelle indeholdende denne dna | |
| DE69233463D1 (de) | Expression und reinigung von kloniertem humanen alpha-fetoprotein | |
| ES2104600T3 (es) | Polipeptido que tiene actividad del factor quimiotactico de los monocitos humanos y adn que codifica dicho polipeptido. | |
| NL930010I1 (nl) | Recombinant DNA-moleculen en de produktie daarvan. | |
| ES2063162T3 (es) | Nuevo sistema de expresion. | |
| ATE175237T1 (de) | Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung. | |
| DK0643719T3 (da) | Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor | |
| AR011110A1 (es) | Promotor del gen de endoglina humana, una construccion de acido nucleico que comprende al menos una secuencia promotora del gen de endoglina humana, unacelula que alberga dicha construccion de acido nucleico, y el uso de dicha construccion de acido nucleico para preparar un farmaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD1A | Patent lapsed |
Effective date: 20060327 |